Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At J.P. Morgan, Ironwood, Shire and Biogen Idec Contemplate What’s Next

Executive Summary

A trio of companies offer insight into their latest strategies from interviews and presentations at the recent J.P. Morgan Healthcare conference: Ironwood’s development pipeline includes seven GI drugs; R&D consolidation and pipeline review at Shire; Biogen preps for hemophilia market and MS pricing pressures.

Advertisement

Related Content

R&D In Brief: Imaging Agent Approvals, EULAR Updates, Post-ASCO Cancer Data
R&D Briefs: Alprolix Approval Bodes Well, T-VEC Stumbles, Curis Back On Track
As Baxter Embarks On A New Course, It Bolsters Its Hemophilia Franchise
Biogen Sets Aside Cash For Business Development, Expects New Launches In 2014
Launching Linzess Into A Tough Primary Care Market

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055892

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel